|
|
|
BusinessWeek Rankings  2007 #46  2007 #49 2006 #18 Merck & Co., Inc. provides various products for human and animal health in the United States and internationally. The company’s Pharmaceutical segment includes human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Zocor, an atherosclerosis product; Cosopt and Trusopt, the ophthalmological products; Primaxin and Cancidas, the anti bacterial/anti fungal products; Januvia and Janumet for type 2 diabetes; Maxalt, an acute migraine product; Proscar to treat symptomatic benign prostate enlargement; Propecia for the treatment of male pattern hair loss; Arcoxia to treat arthritis and pain; Crixivan and Stocrin for the treatment of HIV infection; Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting; and Invanz for treating infection. Merck & Co.’s Vaccines segment comprises human health vaccine products, such as preventative pediatric, adolescent, and adult vaccines administered at physician offices. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; RotaTeq to protect against rotavirus gastroenteritis in infants and children; Zostavax for preventing shingles; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; and M-M-R II, a vaccine against measles, mumps, and rubella. Merck & Co. has agreements with Neuromed Pharmaceuticals, Ltd., FoxHollow Technologies, Inc., Ariad Pharmaceuticals, Inc., Dynavax Technologies Corp., and GTX, Inc, as well as collaboration with Metabasis Therapeutics, Inc. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. Analysts'
Recommendation: | Buy | | 30 Days Ago: | Buy |
| | Analysts' Target: | $55 | | Analysts' Targets | | UBS Securities | $43 | | Hold | Wednesday, June 11, 2008
| | Deutsche Bank Securities | $51 | | Accumulate | Tuesday, April 29, 2008
| | Lehman Brothers | $53 | | Equalweight | Tuesday, April 29, 2008
| | BMO Capital Markets | $60 | | Outperform | Friday, March 28, 2008
| | Bear Stearns & Co. | $69 | | Hold | | Wednesday, December 05, 2007 | | Currency | US Dollars | | Share Price | $36.00 | | Change Today | $1.14 | | 52 Week High | $61.25 | | 52 Week Low | $34.68 | | Volume | 14,243,066 | | Shares Issued | 2,172.50m | | Market Cap | $78,210m | | Beta | 0.64 | | RiskGrade | 174 | <!-- -- END secondColHolder ----> | Strong Buy | 8 | | Buy | 1 | | Neutral | 7 | | Sell | 0 | | Strong Sell | 0 | | Total | 16 |  | 12:42 | 3 @ $36.00 ( green colour )
| | 12:42 | 2 @ $36.00 ( green colour)
| | 12:42 | 3 @ $36.00 ( red colour)
| | 12:42 | 4 @ $36.01 (blue colour)
| | 12:42 | 3 @ $36.00 ( green colour)
|
|
Update 07/27:
7. Merck‘s (MRK) shares can be moved by patent expirations, generic competition, FDA announcements of drug side-effects, and its acquisition of Schering-Plough. Its stock is also subject to trading based on news from the Big Pharma and biotech industries and the Administration’s new healthcare plans. Merck is the sixth most shorted stock among all companies listed on the NYSE. There are 164 million shares short in the company and daily trading volume is almost 20 million shares. Merck’s stock has been as high as $31 this year and as low as $20.
|
MRK:
This call was made
on 06/19/08
@ $35.89
| Rating: |
$35.89 (06/19/08)
|
| Gain/Loss: |
+2.45%
in
533 days
|
| Target: |
$69.00
(+92.25%)
in > one year
|
| Allocation: |
0.3% of portfolio
|
|
